{
    "clinical_study": {
        "@rank": "90903", 
        "arm_group": {
            "arm_group_label": "Armodafinil", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as\n      a means of improving residual daytime sleepiness in patients with treated nocturia."
        }, 
        "brief_title": "A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia", 
        "condition": [
            "Nocturia", 
            "Daytime Sleepiness"
        ], 
        "condition_browse": {
            "mesh_term": "Nocturia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Receiving standard-of-care therapy for nocturia based on assessment by study\n             physician\n\n          2. Evaluation by study physician indicates that the patient meets criteria for either\n             overactive bladder diagnosis, or nocturnal polyuria diagnosis.\n\n          3. Mean number of nocturia episodes at least 2 per night based on day sleep/bladder\n             diary\n\n          4. Epworth Sleepiness Scale Score of at least 10\n\n          5. Clinical Global Impression of Sleepiness at least Moderate\n\n          6. Age 18-90 years inclusive\n\n        Exclusion Criteria:\n\n          1. Medications affecting urinary or sleep-wake function other than therapy for OAB o or\n             NP within 5 half-lives of baseline assessment\n\n          2. Sleep disorders other than nocturia based on history and screening assessment\n\n          3. Unstable medical or psychiatry conditions\n\n          4. Medical or psychiatric conditions affecting sleep/wake or urologic function\n\n          5. Apnea-Hypopnea Index (AHI) \u2265 15 on screening polysomnogram\n\n          6. Periodic Leg Movement Arousal Index (PLMAI) \u2265 15 on screening polysomnogram\n\n          7. History of substance abuse or dependence in the last year\n\n          8. Regular consumption of over 800 mg of caffeine use\n\n          9. Shift-work in the 3 months prior to or during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151253", 
            "org_study_id": "Pro00028116"
        }, 
        "intervention": {
            "arm_group_label": "Armodafinil", 
            "intervention_name": "Armodafinil 50 - 250 mg pills", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Modafinil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Nocturia", 
            "Daytime sleepiness"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "jenny.bridgers@duke.edu", 
                "last_name": "Jenny Bridgers", 
                "phone": "919-684-0752"
            }, 
            "contact_backup": {
                "email": "mark.mayo@duke.edu", 
                "last_name": "Mark Mayo", 
                "phone": "919-681-8392"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Andrew D Krystal, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Andrew Krystal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Epworth score.", 
            "measure": "Change in Epworth Sleepiness Scale", 
            "safety_issue": "No", 
            "time_frame": "Week 2, Week 4, of each phase"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151253"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical Global Impressions, change in severity of excessive daytime sleepiness (EDS)", 
                "safety_issue": "No", 
                "time_frame": "Week 2, week 4, of each phase"
            }, 
            {
                "measure": "Number of naps", 
                "safety_issue": "No", 
                "time_frame": "Baseline; week 4 of each phase."
            }, 
            {
                "measure": "Number of minutes napped based on sleep diary", 
                "safety_issue": "No", 
                "time_frame": "Baseline; week 4 of each phase."
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}